Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 1,719 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $157.28, for a total value of $270,364.32. Following the transaction, the chief marketing officer now owns 56,143 shares in the company, valued at $8,830,171.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Tuesday, January 2nd, Jeffrey Chodakewitz sold 3,438 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $151.80, for a total value of $521,888.40.
  • On Friday, November 3rd, Jeffrey Chodakewitz sold 5,390 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $144.71, for a total value of $779,986.90.
  • On Tuesday, October 31st, Jeffrey Chodakewitz sold 60,000 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $145.05, for a total value of $8,703,000.00.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ VRTX) opened at $157.97 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $80.06 and a 52-week high of $167.85. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $39,753.79, a price-to-earnings ratio of 202.53, a price-to-earnings-growth ratio of 1.86 and a beta of 1.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.49. The company had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The company’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same period last year, the company earned $0.16 earnings per share. equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.77 EPS for the current fiscal year.

Several brokerages recently issued reports on VRTX. BMO Capital Markets restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th. Robert W. Baird restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. JPMorgan Chase & Co. restated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, January 9th. Cowen restated a “buy” rating and set a $200.00 price objective on shares of Vertex Pharmaceuticals in a research note on Monday, December 11th. Finally, Bank of America upgraded Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $180.00 price objective on the stock in a research note on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twenty-five have issued a buy rating and one has given a strong buy rating to the stock. Vertex Pharmaceuticals has an average rating of “Buy” and a consensus target price of $175.89.

Several institutional investors and hedge funds have recently modified their holdings of VRTX. Jennison Associates LLC increased its holdings in shares of Vertex Pharmaceuticals by 19.0% during the third quarter. Jennison Associates LLC now owns 6,017,766 shares of the pharmaceutical company’s stock valued at $914,941,000 after purchasing an additional 962,644 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Vertex Pharmaceuticals by 8,061.1% during the third quarter. Point72 Asset Management L.P. now owns 909,230 shares of the pharmaceutical company’s stock valued at $138,239,000 after purchasing an additional 898,089 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Vertex Pharmaceuticals by 9,422.3% during the third quarter. Assenagon Asset Management S.A. now owns 893,380 shares of the pharmaceutical company’s stock valued at $135,829,000 after purchasing an additional 883,998 shares during the period. Vanguard Group Inc. increased its holdings in shares of Vertex Pharmaceuticals by 3.1% during the second quarter. Vanguard Group Inc. now owns 16,979,872 shares of the pharmaceutical company’s stock valued at $2,188,196,000 after purchasing an additional 504,982 shares during the period. Finally, Fred Alger Management Inc. increased its holdings in shares of Vertex Pharmaceuticals by 34.3% during the second quarter. Fred Alger Management Inc. now owns 1,624,480 shares of the pharmaceutical company’s stock valued at $209,347,000 after purchasing an additional 414,501 shares during the period. 93.19% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells $270,364.32 in Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-cmo-sells-270364-32-in-stock/1815491.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.